Literature DB >> 25081533

Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.

Lilly Y W Bourguignon1, Marisa Shiina2, Jian-Jian Li3.   

Abstract

Hyaluronan (HA), a major component of the extracellular matrix (ECM), is enriched in many types of tumors. There is good evidence linking high levels of HA production in human carcinomas to an aggressive phenotype and tumor metastasis. HA is generally bound to CD44 isoforms (so-called CD44s and CD44v3) which are ubiquitous, abundant, and functionally important cell surface receptors. This chapter describes the evidence for HA/CD44v3-mediated activation of the cytoskeleton (e.g., ankyrin and GTPases) and matrix metalloproteinase (MMP) signaling during tumor progression. A special focus is placed on the role of HA-CD44v3 interaction in cancer stem cells (CSCs). Matrix HA is known to be present in CSC niches. Since CD44v3 serves as a CSC marker, it provides an important physical linkage between matrix HA and various transcription factors that regulate tumor cell functions through distinct signaling pathways. CSCs are known to be chemoresistant and/or radiation resistant and to cause cancer relapse. The purpose of this chapter is to review the most current research on the cellular and molecular biology of CSCs. The emphasis will be placed on both CSC niche and matrix HA-induced microRNA signaling plus various CSC functions (e.g., self-renewal, differentiation, and chemoresistance) during cancer progression. Understanding the regulation of CSCs is critically important for designing CSC-specific therapeutic targets to prevent cancer development and progression.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD44; Cancer stem cells; Chemoresistance; Matrix hyaluronan; Radiation resistance; Tumor progression; microRNAs

Mesh:

Substances:

Year:  2014        PMID: 25081533      PMCID: PMC6759082          DOI: 10.1016/B978-0-12-800092-2.00010-1

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  52 in total

Review 1.  Heralding a new paradigm in 3D tumor modeling.

Authors:  Eliza L S Fong; Daniel A Harrington; Mary C Farach-Carson; Hanry Yu
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

2.  Intermediate Molecular Mass Hyaluronan and CD44 Receptor Interactions Enhance Neutrophil Phagocytosis and IL-8 Production via p38- and ERK1/2-MAPK Signalling Pathways.

Authors:  Cheng-Hsun Lu; Chia-Huei Lin; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Yu-Min Kuo; Ting-Syuan Lin; Chia-Li Yu; Song-Chou Hsieh
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

3.  Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma.

Authors:  Nidhi Jariwala; Devaraja Rajasekaran; Rachel G Mendoza; Xue-Ning Shen; Ayesha Siddiq; Maaged A Akiel; Chadia L Robertson; Mark A Subler; Jolene J Windle; Paul B Fisher; Arun J Sanyal; Devanand Sarkar
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Ivan J M Bonet; Dionéia Araldi; Eugen V Khomula; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2020-07-14       Impact factor: 6.167

5.  CD44 Signaling Mediates High Molecular Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Luiz F Ferrari; Eugen V Khomula; Dioneia Araldi; Jon D Levine
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

6.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

Review 7.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

Review 8.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.

Authors:  Yongmin Yan; Xiangsheng Zuo; Daoyan Wei
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

9.  The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis.

Authors:  Liang Xue; Yi Wang; Shuyuan Yue; Jianning Zhang
Journal:  Neurol Sci       Date:  2016-09-15       Impact factor: 3.307

10.  Osteoblast-released Matrix Vesicles, Regulation of Activity and Composition by Sulfated and Non-sulfated Glycosaminoglycans.

Authors:  Johannes R Schmidt; Stefanie Kliemt; Carolin Preissler; Stephanie Moeller; Martin von Bergen; Ute Hempel; Stefan Kalkhof
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.